Showing results (2231-2240 of 8,887) with videos related to
Sort By:
Pageof 889
European Urology|January 1, 1989
Surgical correction of severe Peyronie's disease without plaque excision. A new approachJ S Sampaio, A PassarinhoEuropean Urology|May 4, 2015
Precision and predictive medicine in urothelial cancer: are we making progress?Joaquim Bellmunt, Anna Orsola, Guru SonpavdeEuropean Urology|January 1, 1980
The curability if invasive bladder cancer treated by radical cystectomyJ J Bredael, B P Croker, J F GlennEuropean Urology|January 1, 1980
Intravesical instillation of Adriamycin. A model for standardization of the chemotherapyS Eksborg, S O Nilsson, F EdsmyrEuropean Urology|January 1, 1997
A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancerJ M Kuhn, H Abourachid, P Brucher, et al.European Urology|January 1, 1997
Bladder biofeedback for the treatment of refractory sensory urgency in adultsJ J Wyndaele, L Hoekx, A VermandelEuropean Urology|January 1, 1997
Short- and mid-term outcome of different types of one-stage hypospadias correctionsM Sorber, W F Feitz, J D de VriesEuropean Urology|January 1, 1997
Detection of telomerase activity in prostate cancer by needle biopsyC Takahashi, I Miyagawa, S Kumano, et al.European Urology|January 1, 1997
Orthotopic reconstruction in a woman following cystectomy and cutaneous urinary diversion. The 1st reported caseJ P Stein, D A Ginsberg, G D Grossfeld, et al.European Urology|March 31, 1998
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative GroupH J de Voogt, U Studer, F H Schröder, et al.Pageof 889